Literature DB >> 12702191

Low frequency of observed anti-HLA among transfused preterm infants.

Naohisa Ishibashi1, Hitoshi Ohto, Niro Ujiie, Hiromichi Ariga, Tsutomu Ishii, Hitoshi Suzuki.   

Abstract

BACKGROUND: Although low-birth-weight infants (LBWI) often receive multiple transfusions, there is controversial information on their development of antibodies against WBCs or platelets. STUDY DESIGN AND METHODS: A total of 52 LBWI with birth weights less than 1500 g were randomly assigned to receive either RBCs that had been WBC- reduced (n = 25) or nonfiltered blood (n = 27). Serum samples collected from 37 infants at 3 months of age and from 30 children when they were 5 to 11 years old were tested. Anti-HLA was assayed with an anti-human globulin-augmented lymphocytotoxicity test against a panel consisting of 13 lymphocytes and against parental cells.
RESULTS: None of 52 transfused LBWI of either group developed anti-HLA (95% CI, 0%-6.8% for overall, 0%-13.7% for the WBC-reduced group, and 0%-12.7% for the nonfiltered group).
CONCLUSION: Multiply transfused LBWI rarely produced antibodies to HLA of blood donors and to noninherited maternal antigens. The benefits of WBC reduction to prevent HLA alloimmunization during infancy were not supported by this study and need further investigation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12702191     DOI: 10.1046/j.1537-2995.2003.00378.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  2 in total

1.  Paediatrics: Infant dialysis--what makes it special?

Authors:  Lesley Rees
Journal:  Nat Rev Nephrol       Date:  2012-11-27       Impact factor: 28.314

2.  Washing red cells after leucodepletion does not decrease human leukocyte antigen sensitization risk in patients with chronic kidney disease.

Authors:  Antony Aston; Rebecca Cardigan; Saber Bashir; Susan Proffitt; Helen New; Colin Brown; Ri Liesner; Sylvia Hennem; Helen Nulty; Olivia Shaw; Robert Vaughan; Jon Jin Kim; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2014-04-29       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.